



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2023 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 926 293 621
Organisasjonsform: Aksjeselskap
Foretaksnavn: GE HEALTHCARE NORGE AS
Forretningsadresse: Vitaminveien 1A
0485 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2023 - 31.12.2023

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Georg Grøndalen
Dato for fastsettelse av årsregnskapet: 27.06.2024

Grunnlag for avgivelse

År 2023: Årsregnskapet er elektronisk innlevert
År 2022: Tall er hentet fra elektronisk innlevert årsregnskap fra 2023

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 09.07.2025



Resultatregnskap

Beløp i: NOK	Note	2023	2022
RESULTATREGNSKAP			
Inntekter			
Sales revenues	2	298 283 000	245 995 000
Other operating income		157 000	1 237 000
Sum inntekter		298 440 000	247 231 000
Kostnader			
Raw materials and consumables		182 335 000	139 057 000
Employee benefits expense	3	58 064 000	53 935 000
Depreciations and amortisations		329 000	333 000
Nedskrivning av varige driftsmidler og immaterielle eiendeler	4		
Other expenses	3, 5	45 523 000	43 589 000
Sum kostnader		286 250 000	236 915 000
Driftsresultat		12 190 000	10 317 000
Finansinntekter og finanskostnader			
Income from subsidiaries	6		
Income from other group companies	6		
Group contribution received	6		
Renteinntekt fra foretak i samme konsern	6	5 339 000	14 665 000
Annen renteinntekt	6		
Other financial income			3 000
Sum finansinntekter		5 339 000	14 668 000
Impairment of shares in subsidiaries	6		
Write-down of long-term investments	6		
Rentekostnad til foretak i samme konsern	6		12 546 000
Annen rentekostnad	6	31 000	46 000
Other financial expenses		3 305 000	263 000
Sum finanskostnader		3 337 000	12 855 000
Netto finans		2 002 000	1 813 000
Ordinært resultat før skattekostnad		14 192 000	12 130 000
Income tax expense	7	3 249 000	2 673 000



Resultatregnskap

Beløp i: NOK	Note	2023	2022
Ordinært resultat etter skattekostnad		10 944 000	9 457 000
Årsresultat		10 944 000	9 457 000
Årsresultat etter minoritetsinteresser		10 944 000	9 457 000
Totalresultat		10 944 000	9 457 000
Overføringer og disponeringer			
Transferred from reserve for valuation variances	9		
Konsernbidrag	8	12 160 000	16 327 000
Avgitt konsernbidrag	8, 9		
Udekket tap	9		
Other equity	9		
Transfer to/from other equity	9	-1 216 000	-6 871 000
Sum overføringer og disponeringer		10 944 000	9 457 000



Balanse

Beløp i: NOK	Note	2023	2022
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Development	4		
Patents, licences, etc.	4, 10		
Utsatt skattefordel	7	8 845 000	8 664 000
Goodwill	4		
Sum immaterielle eiendeler		8 845 000	8 664 000
Varige driftsmidler			
Buildings and land	4		
Machinery and other equipment	4	670 000	999 000
Assets under construction	4		
Equipment and other movables	4		
Sum varige driftsmidler		670 000	999 000
Finansielle anleggsmidler			
Investering i datterselskap	11		
Investering i annet foretak i samme konsern	10		
Lån til foretak i samme konsern	10		
Investeringer i tilknyttet selskap	10		
Sum anleggsmidler		9 516 000	9 663 000
Omløpsmidler			
Varer			
Sum varer	12	3 965 000	7 103 000
Fordringer			
Accounts receivables		94 879 000	60 298 000
Other current receivables		328 000	1 302 000
Konsernfordringer		152 336 000	112 782 000
Sum fordringer		247 542 000	174 383 000
Cash and cash equivalents	13		
Sum omløpsmidler		251 507 000	181 486 000



Balanse

Beløp i: NOK	Note	2023	2022
SUM EIENDELER		261 023 000	191 149 000
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Share capital	9	1 114 000	1 114 000
Overkurs	9	109 842 000	95 469 000
Annen innskutt egenkapital	9		
Sum innskutt egenkapital		110 956 000	96 583 000
Other equity	9		
Sum egenkapital		110 956 000	96 583 000
Gjeld			
Langsiktig gjeld			
Utsatt skatt	7		
Annen langsiktig gjeld			
Gjeld til kredittinstitusjoner	10		
Langsiktig konserngjeld	10		
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Konvertible lån		35 529 000	34 625 000
Sertifikatlån		8 276 000	7 103 000
Leverandørgjeld	10	62 692 000	23 807 000
Tax payable	7		
Public duties payable		26 444 000	13 972 000
Kortsiktig konserngjeld	10	1 075 000	
Other current liabilities	14	16 051 000	15 060 000
Sum kortsiktig gjeld		150 066 000	94 566 000
Sum gjeld		150 066 000	94 566 000
SUM EGENKAPITAL OG GJELD		261 023 000	191 149 000



Balanse

Beløp i: NOK	Note	2023	2022
---------------------	-------------	-------------	-------------



GE Healthcare Norge AS

Årsberetning 2023

VIRKSOMHETENS ART

Selskapets virksomhet er import, markedsføring, installasjon og service på medisinsk teknisk utstyr til offentlige og private sykehus og helseinstitusjoner. Den største delen av salget er til norske kunder (83% i 2023), men selskapet har også vesentlig salg til Frankrike og Island.

GE Healthcare Norge AS er et heleid datterselskap av GE Healthcare Holding Norge AS et selskap eid (indirekte) av GE Healthcare Technologies Inc (GE HealthCare) i USA.

GE HealthCare ble offisielt skilt fra General Electric Company 3. januar 2023. Selskapets nye ultimate morselskap er GE HealthCare Technologies Inc, som erstatter General Electric Company (GE). GE HealthCare Holding LLC ble dannet som et aksjeselskap med begrenset ansvar i Delaware 16. mai 2022 med det formål å motta alle netto eendeler til GE HealthCare. Den 29. desember 2022 konverterte GE HealthCare Holding LLC til et Delaware-selskap og ble omdøpt til GE HealthCare Technologies Inc. Separasjonen ble fullført 3. januar 2023 gjennom en distribusjon på omtrent 80,1% av ordinære aksjer i GE HealthCare Technologies Inc til eiere av oversikt over GEs ordinære aksjer ved avslutning av virksomheten 16. desember 2022, og GE HealthCare Technologies Inc ble et uavhengig offentlig selskap, notert under symbolet "GEHC" på Nasdaq Stock Market LLC. Adressen til selskapets nye ultimate morselskap er 500 W. Monroe Street, Chicago, IL 60661, USA.

FORTSATT DRIFT

I samsvar med regnskapslovens § 3-3a bekreftes det at forutsetningen om fortsatt drift er lagt til grunn ved avleggelsen av årsregnskapet.

RESULTAT, INVESTERINGER, FINANSIERING OG LIKVIDITET

I 2023 hadde selskapet en omsetningsvekst på 21%, fra 246 millioner NOK i 2022 til 298 millioner NOK i 2023. Denne veksten skyldes hovedsakelig økt salg i Imaging-segmentet, mens Patient Care Solutions (PCS) og service-segmentet holdt seg på samme nivå som i 2022. I 2023 utgjorde interne konserntransaksjoner 5% av omsetningen, sammenlignet med 7% i 2022.

De største kundene til GE Healthcare Norge AS er offentlige sykehus i Norge. Økningen i salg kan i stor grad tilskrives god kontinuitet hos eksisterende kunder, salg til nye kunder, inflasjon og fordelaktig valuta for selskapets eksport.

Driftsresultatet for 2023 endte på 12,2 millioner NOK, mot 10,3 millioner NOK i 2022. Dette innebærer at resultatet er på linje med tidligere år, ettersom kostnadene har økt i takt med inntektene.

Selskapets totale gjeld per 31.12.2023 var 150 millioner NOK, sammenlignet med 95 millioner NOK per 31.12.2022. Denne økningen skyldes hovedsakelig en økning i kortsiktig gjeld innenfor konsernet. Leverandørgjeld til eksterne var 14 millioner NOK i 2023, noe som anses adekvat for selskapets størrelse. Egenkapitalen utgjorde 43% av totalkapitalen i 2023, mot 50,5% i 2022. Netto kontantstrøm fra operasjonelle aktiviteter var 39,5 millioner kroner i 2023, sammenlignet med -45,2 millioner kroner i 2022. Endringen skyldes hovedsakelig en vesentlig økning i kundefordringer per 31.12.2023 sammenlignet med 31.12.2022, samt en tilsvarende økning i leverandørgjeld, noe som har stabilisert kontantstrømmen på et nivå tilsvarende tidligere år.

FINANSIELL RISIKO

Selskapet er utsatt for kreditt risiko, renterisiko og valutarisiko i dens ordinære forretningsvirksomhet, og styrer mot å ha en akseptabel risiko innenfor disse områdene. Alle nye kunder blir kredittvurdert ved inngåelse av salgskontrakter. Salget skjer fortrinnsvis i lokal valuta, og gjeld i utenlandsk valuta betales



omgående. Selskapet har i all hovedsak rentebærende gjeld/ fordringer med flytende rentesats og er derfor eksponert for endringer i kortsiktige renter.

Selskapet dekker sitt finansieringsbehov gjennom den løpende driften og gjennom konsernets konsernkonto-ordning hvor likviditet kan plasseres og hentes. Selskapets finansieringsaktiviteter følges opp av den lokale finansavdelingen i samarbeid med den sentrale Treasury funksjonen i konsernet, og kontrolleres av foretakets ledelse og styre.

GE HealthCare har tegnet en felles ansvarsforsikring som styrets medlemmer og daglig leder er dekket av for deres mulige ansvar overfor foretaket og tredjepersoner.

ARBEIDSMILJØ OG PERSONALE

Sykefraværet endte på 0,62% % i år 2023 sammenlignet med 2,0% i år 2022 og anses for å være på et tilfredsstillende lavt nivå og følges opp i henhold til gjeldende regler. Det har ikke vært registrert noen arbeidsulykker eller skader på arbeidsplassen i år 2023.

REDGJØRELSE OM SAMFUNNSANSVAR

GE HealthCare støtter og respekterer internasjonale menneskerettsprinsipper og arbeider for å sikre at konsernet ikke er involvert i saker knyttet til brudd på menneskerettigheter. Dette gjør vi gjennom å respektere internasjonale og lokale arbeidsvilkår, tilby produkter som tilfredsstiller våre kunders behov så vel som gjeldende krav til sikkerhet og spesifikasjoner, og ved å kvalitetssikre våre kunder, leverandører og samarbeidspartnere.

GE HealthCare har retningslinjer som beskriver hvordan ansatte skal håndtere etiske spørsmål i forhold til kollegaer, leverandører og samarbeidspartnere. Alle nyansatte må gjennom opplæring for å bli bevisst på dette og å trenes opp i hvordan ulike situasjoner skal håndteres riktig.

Selskapet jobber aktivt med å bekjempe all form for korrupsjon. Som en del av GE HealthCare konsernet har vi robuste interne regnskapsprosesser og regelverk, og bruker betydelige ressurser på å sikre at dette overholdes. GE HealthCare forbyr uttrykkelig urettmessige betalinger i alle situasjoner og har implementert strukturerte og velfungerende kontrollprosesser for å sikre at dette ikke skjer.

Selskapet er omfattet av åpenhetsloven og har plikt til å publisere redegjørelse etter åpenhetsloven fra og med 30. juni 2023. Redegjørelsen er tilgjengelig på GE HealthCare konsernet sin nettside på følgende nettadresser:

<https://www.gehealthcare.com/about/suppliers/terms-and-conditions>

<https://www.gehealthcare.com/-/jssmedia/gehc/us/images/about-us/suppliers/requirement/new/supplier-integrity-guide-english-jan-2023.pdf?rev=-1>

<https://www.gehealthcare.no/-/jssmedia/gehc/no/files/norway-transparency-act-2023-vf-ib00191no.pdf?rev=-1>

REDGJØRELSE OM LIKESTILLING

Selskapets styre består av fire menn. Ved utgangen av året er det 42 ansatte, hvorav 12 er kvinner.

Selskapet er tilfreds med kjønnsbalansen i arbeidsstokken. Vi tror på å fremme høyt kompetente personer til rett stilling til rett tid basert på praksis og holdninger, snarere enn å la kjønn være en avgjørende faktor. Kompetanse, holdninger og samarbeidsevner er de viktigste kriteriene for ansettelse og forfremmelse på alle nivåer. I rekrutteringssammenheng fokuserer vi på å sette sammen balanserte team med varierte kompetanse- og personlighetsprofiler, noe som styrker både kjønnsfordelingen og mangfoldet generelt.

I samsvar med GE HealthCare sin adferdskodeks skal selskapet og de ansatte medvirke til at det skapes en atmosfære der rettfærdige ansettelsesvilkår gjelder for alle medlemmer i et mangfoldig GE HealthCare-fellesskap.



MILJØRAPPORTERING

Selskapets virksomhet forurenses ikke det ytre miljø.

FREMTIDIG UTVIKLING

Selskapet streber etter å kontinuerlig å tilpasse seg markedet vi opererer i og ønsker å være i forkant av markedet hva gjelder trender og kompetanseheving. Selskapet har en god ordresreserve og det planlegges flere store produktlanseringer som vil være med på å ytterligere styrke vår posisjon i det Norske markedet. Vi arbeider med samkjøring av salgs og service organisasjonene innenfor GE Healthcare konsernet.

Det er ikke planlagt større investeringer eller omstruktureringer i år 2024. Selskapet vil løpende vurdere behovet for å tilpasse arbeidsstokken i takt med markedsutviklingen.

HENDELSER ETTER BALANSEDAGEN

Det har ikke inntruffet vesentlige forhold etter 31.12.2023 som er av betydning for bedømmelsen av selskapets stilling som ikke fremkommer av årsregnskapet med tilhørende noter.

ÅRSRESULTAT OG DISPONERINGER

Styret er av den oppfatning at årsregnskapet gir et rettvise bilde over utviklingen og resultatet til selskapet samt selskapets eiendeler, gjeld og finansielle stilling.

Styret foreslår at overskuddet disponeres som følger:

Avgitt konsernbidrag (netto)	NOK	12 159 897
Overført fra annen innskutt EK	NOK	-1 216 364
Sum disponering (Årsresultat)	NOK	10 943 533

Oslo, 20.06.2024

I styret for GE Healthcare Norge AS,

Pål Arne Wøien
Styreleder

Rune Kristoffersen
Styremedlem

Gunnar Arveschoug
Styremedlem / Daglig Leder

Georg Grøndalen
Styremedlem



Deloitte.

Deloitte AS
Dronning Eufemias gate 14
Postboks 221
NO-0103 Oslo
Norway

+47 23 27 90 00
www.deloitte.no

To the General Meeting of Ge Healthcare Norge AS

INDEPENDENT AUDITOR'S REPORT

Opinion

We have audited the financial statements of Ge Healthcare Norge AS (the Company), which comprise the balance sheet as at 31 December 2023, the income statement, statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements, and
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2023, and its financial performance and its cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report and the other information accompanying the financial statements. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report nor the other information accompanying the financial statements.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report and the other information accompanying the financial statements. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the other information accompanying the financial statements and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report and the other information accompanying the financial statements otherwise appear to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report or the other information accompanying the financial statements. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

Deloitte AS and Deloitte Advokatfirma AS are the Norwegian affiliates of Deloitte NSE LLP, a member firm of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"). DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte NSE LLP do not provide services to clients. Please see www.deloitte.com/about to learn more about our global network of member firms.

Deloitte Norway conducts business through two legally separate and independent limited liability companies: Deloitte AS, providing audit, consulting, financial advisory and risk management services, and Deloitte Advokatfirma AS, providing tax and legal services.

Registrert i Foretaksregisteret
Medlemmer av Den norske Revisorforening
Organisasjonsnummer: 980 211 282



Independent auditor's report
Ge Healthcare Norge AS

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error. We design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves a true and fair view.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Oslo, 28 June 2024
Deloitte AS

Morten Østigård
State Authorised Public Accountant
(electronically signed)



Independent auditor's report - GE HC Norge AS

Name	Date
Østigård, Morten	2024-06-28

Identification

 bankID Østigård, Morten



This document contains electronic signatures using EU-compliant PAdES - PDF
Advanced Electronic Signatures (Regulation (EU) No 910/2014 (eIDAS))



GE Healthcare Norge AS Financial Statements 2023

All figures in NOK '000

Profit & Loss Statement		01.01 - 31.12	01.01 - 31.12
	Note	2023	2022
REVENUES			
Sales revenues	2, 3	298,440	245,995
Other operating income	2	0	1,237
Total revenues		298,440	247,231
OPERATING EXPENSES			
Cost of goods sold		182,335	139,057
Payroll expenses	4	58,064	53,935
Depreciations	5	329	333
Other operating expenses	6	45,523	43,589
Total operating expenses		286,250	236,915
Operating profit		12,190	10,317
FINANCIAL INCOME AND EXPENSES			
Interest received from group companies	3	5,339	14,665
Other financial income		0	3
Interest paid to group companies	3	0	-12,546
Other financial expenses		-3,337	-309
Net financial income and expenses		2,002	1,813
Ordinary profit before tax		14,192	12,130
Tax expense	7	3,249	2,673
Ordinary profit after tax		10,944	9,457
Transfers			
Group contribution (net)	8	12,160	16,327
Transferred to other equity	8	-1,216	-6,871
Total		10,944	9,457



GE Healthcare Norge AS Financial Statements 2023

All figures in NOK '000

Balance Sheet

	Note	31.12.2023	31.12.2022
ASSETS			
NON-CURRENT ASSETS			
Intangible assets			
Deferred tax asset	7	8,845	8,664
Total intangible assets		8,845	8,664
Tangible assets			
Furniture, equipment and tools	5	670	999
Assets under construction	5	0	0
Total tangible assets		670	999
Total non-current assets		9,516	9,663
CURRENT ASSETS			
Inventories	9	3,965	7,103
Receivables			
Trade receivables		94,879	60,298
Short term receivables from group companies	3	152,336	112,782
Other current receivables		328	1,302
Total receivables		247,542	174,383
Cash and cash equivalents	10	0	0
Total current assets		251,507	181,486
Total assets		261,023	191,149



GE Healthcare Norge AS
Financial Statements 2023

All figures in NOK '000

Balance Sheet

	Note	31.12.2023	31.12.2022
EQUITY AND LIABILITIES			
EQUITY			
Paid-in equity			
Share capital	11	1,114	1,114
Other paid-in equity	11	109,842	95,469
Total paid-in equity		110,956	96,583
Earned equity			
Retained earnings	11	0	0
Total earned equity		0	0
Total equity		110,956	96,583
LIABILITIES			
CURRENT LIABILITIES			
Trade payables		62,692	23,807
Public duties payable		26,444	13,972
Short term debt to group companies	3	1,075	0
Deferred income		8,276	7,103
Accruals for future obligations	12	35,529	34,625
Other current liabilities	13	16,051	15,060
Total current liabilities		150,066	94,566
Total liabilities		150,066	94,566
Total equity and liabilities		261,023	191,149

Oslo, 20 June 2024

Pål Arne Wøien
Chairman of the Board
(sign.)

Gunnar Arveschoug
General Manager / Board Member
(sign.)

Georg Grøndalen
Board Member
(sign.)

Rune Kristoffersen
Board Member
(sign.)



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Cash Flow Statement

	01.01 - 31.12	01.01 - 31.12
	2023	2022
Cash flow from operating activities		
Ordinary profit before tax	14,192	12,130
Depreciations	329	333
Changes in inventories	3,138	-236
Changes in accounts receivable	-34,580	33,680
Changes in accounts payable	38,885	-5,462
Changes in inter-company receivables and debt	1,075	-1,000
Changes in other accrued items	16,515	5,769
Net cash flow from operating activities	39,553	45,216
Cash flow from investment activities		
Net change in cash pool receivable	-39,553	-45,216
Net cash flow from investment activities	-39,553	-45,216
Cash flow from financing activities		
Received group contribution	20,932	13,627
Distributed group contribution	-20,932	-13,627
Net cash flow from financing activities	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents 01.01	0	0
Cash and cash equivalents 31.12	0	0
Net change in cash and cash equivalents	0	0



GE Healthcare Norge AS Financial Statements 2023

All figures in NOK '000

Notes

NOTE 1 ACCOUNTING PRINCIPLES

The annual accounts have been prepared in compliance with the Norwegian Accounting Act and Norwegian generally accepted accounting principles. The annual accounts are presented in thousand Norwegian kroner. Due to rounding off, smaller differences can occur in the totals.

The annual accounts are based on the basic principles of historical cost, comparability, going concern, congruence and prudence. Transactions are recorded at the value of the compensation at the time of the transaction. Revenues are recognized when they are earned and costs matched with earned income. The accounting principles will be explained below. When the actual number is not available at the time when preparing the accounts, the generally accepted accounting principles requires the best possible estimate to be calculated and used in the income statement and balance sheet. It could arise discrepancies between estimated and actual numbers.

Assets/liabilities that relate to the trade cycle and records that are due for payment within one year after the balance sheet date, are classified as current assets/current liabilities. Current assets/short-term debt are assessed to the lowest/highest value of acquisition cost and fair value. Fair value is defined as the estimated future sales price reduced with expected sales costs. Other assets are classified as fixed assets. Fixed assets is assessed at acquisition cost.

Revenue recognition time

Revenues are recognized when they are earned. Revenue recognition occurs normally at the time of delivery of goods and services. When the risk and title are transferred to the customer this is considered as the delivery time. The portion of the sales revenue that relates to future service benefits are capitalized as deferred income and then later recognized in line with the delivery of benefits. Operating revenues are deducted for sales tax, discounts, bonuses and invoiced shipping costs.

Matching / point in time for charge as expense

Expenses are matched with and charged to profits at the same time with the revenues the expenses can be attributed to. Expenses that can not be attributed directly to the revenue are recognized as costs when they are incurred.

Other operating income / expenses

Significant income and expenses that do not have the context of the ordinary course of business, are classified as other operating income and expenses. Records that are unusual, irregular and essential are classified as extraordinary.

Fixed assets

Fixed assets are reflected in the balance sheet and depreciated to residual value over the asset's expected useful life on a straight-line basis. If changes in the depreciation plan occur the effect is distributed over the remaining depreciation period. Direct maintenance of an asset is expensed under operating expenses as and when it is incurred. Additions or improvements are added to the asset's cost price and depreciated together with the asset. The split between maintenance and additions/improvements is calculated in proportion to the asset's condition at the acquisition date.

Impairment tests are carried out if there is indication that the carrying amount of an asset exceeds the estimated recoverable amount. The test is performed on the lowest level of fixed assets at which independent cashflows can be identified. If the carrying amount is higher than both the fair value less cost to sell and recoverable amount (net present value), the asset is written down to the highest of fair value less cost to sell and the recoverable amount.

Operating lease is charged as normal rental cost, and is classified as ordinary operating expenses.

Inventories and cost of goods sold

Inventories of goods are valued at the lower of purchase cost and fair value. This year's cost of goods sold consist of the purchase price sold merchandise and shipping charges. If invoices from the subcontractor are not received at the time of revenue recognition of sales then cost of goods sold is accrued. This will in the balance sheet be classified as short-term debt. Write-down for foreseeable obsolescence is included.

Guarantees

The preparation of financial statements in accordance with generally accepted accounting practice requires that management uses estimates and assumptions that affect the income statement and the valuation of assets and liabilities, as well as information about uncertain assets and liabilities at balance sheet date. Conditional losses that are probable and quantifiable is expensed as incurred.

Foreign currencies

Assets and liabilities in foreign currencies are valued at the exchange rate on the balance sheet date.

Receivables

Trade and other receivables are recorded on the balance sheet at the original invoiced amount net of accrual for expected losses. Accrued losses on receivables are being made based on individual assessments of the receivables.



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Notes

Pension liabilities and pension cost

The company has a defined contribution pension plan that gives employees the right to agreed future pension benefits. Under the defined contribution scheme contributions are recognised as payroll expenses on a continuous basis. The payments are based on underlying wage levels and premium levels. The company has no pension obligations beyond the premium payment.

Deferred tax and tax expenses

The tax charge in the income statement includes both payable taxes for the period and changes in deferred tax. Deferred tax is calculated at relevant tax rates on the basis of the temporary differences which exist between accounting and tax values, and any carryforward losses for tax purposes at the year-end. The effect of change in tax rates is disclosed in the notes. Tax enhancing or tax reducing temporary differences, which are reversed or may be reversed in the same period, have been eliminated. The disclosure of deferred tax benefits on net tax reducing differences which have not been eliminated, and carryforward losses, is based on estimated future earnings. Deferred tax and tax benefits which may be shown in the balance sheet are presented net.

Cash flow statement

The cash flow statement has been prepared according to the indirect method. Cash and cash equivalents include cash, bank deposits, and other short term investments which immediately and with minimal exchange risk can be converted into known cash amounts, with due date less than three months from purchase date. The company is a participant in the GE cash pool arrangement and can draw on this by liquidity needs. No credit limit has been determined. The cash pool balance is classified as intercompany balance and interests are calculated on a daily basis.

Group financial statements

The company is part of the GE Healthcare Norway Group, owned by GE Healthcare Holding AS. The parent company of the Norway Group is GE Medical Holding AB (Sweden) that is member of the GE HealthCare Group, with ultimate parent of GE HealthCare Technologies Inc. listed on the Nasdaq Stock Market LLC from 3 January 2023, following the separation from General Electric Company. GE HealthCare Technologies Inc. prepares annual consolidated financial statements based on US GAAP. These group financial statements include the GE Healthcare Norway Group. Based on this the Norway Group members have been granted the exemption to prepare consolidated financial statements. The group financial statements for GE HealthCare Technologies Inc. can be obtained from www.gehealthcare.com, or by enquiry to GE HealthCare Technologies Inc., with its principal address at 500 W. Monroe Street, Chicago, IL 60661, USA.

NOTE 2 REVENUES

Areas of operation	2023	2022
Medical technical equipment	153,295	102,476
Services and parts	145,145	143,518
Total sales revenues	298,440	245,995
Other operating income	0	1,237
Total revenues	298,440	247,231

Geographical markets	2023	2022
Norway	248,823	223,274
France	35,941	10,892
Iceland	12,001	9,970
Other markets	1,676	1,859
Total revenues	298,440	245,995



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Notes

NOTE 3 TRANSACTIONS AND BALANCES WITH AFFILIATED COMPANIES

Profit and loss statement	Type of transaction	2023	2022
GE Medical Systems Societe en Commandite Simple	Revenues from combined goods / service sales	12,001	10,892
GE Vingmed Ultrasound AS	Revenues from combined goods / service sales	1,720	6,035
GE Healthcare Danmark A/S	Revenues from combined goods / service sales	1,185	0
General Electric Company	Costs for centralized services	0	-2,332
GE Healthcare AS	Cash pool interest received	5,382	14,658
GE Healthcare Treasury Services Unlimited Company	Cash pool interest received	0	7
GE Healthcare Treasury Services Unlimited Company	Cash pool interest paid	-43	0
GE Healthcare AS	Cash pool interest paid	0	-12,546
Net significant transactions with affiliated companies		20,244	16,714

Current receivables	Balance type	31.12.2023	31.12.2022
GE Vingmed Ultrasound AS	Trade receivables	17,516	12,011
GE Healthcare Trade and Development LLC	Trade receivables	0	4,000
GE Medical Systems Societe en Commandite Simple	Trade receivables	3,434	1,775
GE Precision Healthcare LLC	Trade receivables	3,477	0
Other GE affiliated companies	Trade receivables	107	263
Total trade receivables affiliated companies		24,535	18,049

GE Healthcare AS	Cash pool receivable	152,336	112,739
GE Healthcare Treasury Services Unlimited Company	Cash pool receivable	0	43
Total other receivables affiliated companies		152,336	112,782

Current liabilities	Balance type	31.12.2023	31.12.2022
GE Healthcare Trade and Development LLC	Trade payables	15,769	4,654
GE Vingmed Ultrasound AS	Trade payables	16,050	0
GE Medical Systems Societe en Commandite Simple	Trade payables	6,240	2,375
GE Healthcare Sverige AB	Trade payables	1,992	2,155
GE Healthcare Danmark A/S	Trade payables	2,563	2,142
GE Precision Healthcare LLC	Trade payables	1,540	1,543
GE HealthCare Technologies Inc	Trade payables	2,006	0
Other GE affiliated companies	Trade payables	2,168	2,208
Total trade payables affiliated companies		48,327	15,077

GE Healthcare Treasury Services Unlimited Company	Cash pool payable	1,075	0
Total other current liabilities affiliated companies		1,075	0

The company purchases most of its goods from various group companies within the Healthcare group for resale. Agreements with group companies have been established about service and maintenance work towards customers. There is a shared service agreement in place with other group companies to purchase various support services. All contracts and transactions between group companies are conducted on market terms. The specified transaction groups / amount are considered to be the most significant ones for the understanding of the financial statements.

NOTE 4 PERSONNEL EXPENSES, MANAGEMENT REMUNERATION AND AUDIT FEES

Salaries, wages and other employee benefits	2023	2022
Salaries and wages	45,006	43,628
Social security contribution	8,620	6,800
Pension costs	4,024	3,172
Other employee benefits	415	335
Total salaries, wages and other employee benefits	58,064	53,935

Average number of full time employees during the year	42	44
---	----	----



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Notes

Management remuneration

	2023	2022
Salary and bonus expensed	1,993	1,765
Pension costs	113	116
Other benefits	192	158

The General Manager and the Chairman of the Board are member of the GE HealthCare group share option scheme. The scheme provides the assigned the right to buy a stock at face value to the given strike price. The option goes over in the employee's ownership and is thus entitled to dividend from no earlier than at the first redemption date, and no later than at the last redemption date. The expiration date is the last date the employee can realize the option. Options are funded by GE HealthCare Technologies Inc. and only the employer tax related to the option value are accounted for in the company. Below is the number of options with corresponding strike price and redemption time provided for the General Manager and the Chairman of the Board.

Number of options	Strike price USD	Assigned date	Expiry date
552	142.15	05.09.2014	05.09.2024
931	76.66	19.03.2018	19.03.2028
559	57.74	19.03.2019	19.03.2029
961	63.51	02.03.2020	02.03.2030
1,410	70.01	01.02.2023	01.02.2033
<u>4,413</u>			

In addition, the General Manager and the Chairman of the Board are also awarded Restricted Stock Units (RSU) with dividend rights. Each RSU entitles the assigned (1) the right to receive a stock at face value USD 0 given certain restrictions, and (2) cash payments based on the dividends paid to the owners of such shares. Until restrictions expire, or RSU's are cancelled, whatever occurs first, GE HealthCare will pay the assigned cash amounts equal to the number of times each RSU's share of the quarterly dividend payment provided to the shareholders of the ordinary shares. Such payments should be completed fairly quickly after each quarterly payment date.

Number of RSU	Granted	Restrictions expire
1,305	03.08.2020	03.08.2030
669	01.03.2021	01.03.2031
1,312	01.03.2022	01.03.2032
160	01.02.2023	01.02.2050
1,195	01.03.2023	01.03.2050
<u>4,641</u>		

No loans or guarantees have been granted to the General Manager or the Chairman of the Board.

No fees have been paid to the board members.

As of 1 January 2024, General Manager, Anders Olaf Gunby left the company, Gunnar Arveschoug registered as new General Manager.

The above informations on management remuneration including the remuneration for the previous General Manager in 2023.

Auditor

	2023	2022
Remuneration (ex VAT) for statutory audit of the financial year	227	211



GE Healthcare Norge AS
Financial Statements 2023

All figures in NOK '000

Notes

NOTE 5 TANGIBLE ASSETS

	Furniture, equipment	Tools	Assets under construction	Total
First cost as of 1 1	2,927	1,102	0	4,029
Additions	0	0	0	0
Disposals	0	0	0	0
Transfers	0	0	0	0
First cost as of 31 12	2,927	1,102	0	4,029
Accumulated depreciations as of 1 1	2,010	1,020	0	3,030
Depreciation for the year	264	64	0	329
Disposals	0	0	0	0
Transfers	0	0	0	0
Accumulated depreciations as of 31 12	2,274	1,085	0	3,359
Book value as of 1.1.	918	81	0	999
Book value as of 31 12.	653	17	0	670

Useful life	Up to 5 years	Up to 5 years
Depreciation method	Linear	Linear

Tangible asset leasing expenses	2023	2022
Office	5,728	5,832
Vehicles	4,281	5,132
Office equipment and furniture	658	1,139
Total tangible asset leasing expenses	10,667	12,104

The assets are not recognized in the balance sheet as they are not deemed as financial leasing, according to generally accepted accounting principles

NOTE 6 OTHER OPERATING EXPENSES

	2023	2022
Rental expenses	10,725	12,387
Travel and living expenses	9,080	8,623
Commission expenses	6,575	8,040
Transportation and storage costs	4,111	3,978
Consulting services	3,123	1,968
Sundry office expenses	1,678	2,636
Guarantee expenses	3,676	-30
Sales and advertising costs	661	626
Other operating expenses	5,893	5,362
Total other operating expenses	45,523	43,589

NOTE 7 SPECIFICATION OF TAXES

	2023	2022
Calculation of taxable income.		
Profit before tax	14,192	12,130
Permanent differences	574	22
Change in temporary differences	823	8,780
Total taxable income	15,590	20,932
Tax payable	3,430	4,605



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Notes

	2023	2022
Tax expense for the year:		
Tax payable on current year profit	3,430	4,605
Change in deferred tax asset	-181	-1,932
Change in deferred tax asset - change in tax rate	0	0
Total tax expense for the year	3,249	2,673
	2023	2022
Explanation of tax expense for the year:		
Tax on profit before tax	3,122	2,669
Effect from permanent items	126	5
Effect from change in tax rate	0	0
Total tax expense for the year	3,249	2,673
	31.12 2023	31.12 2022
Tax payable in the balance sheet:		
Tax payable on current year profit	3,430	4,605
Tax on paid group contribution	-3,430	-4,605
Total tax liability	0	0
Specification of basis for deferred tax asset:		
Fixed assets	-328	-259
Inventories	-4,647	-5,205
Receivables	-494	-282
Gain and loss account	792	989
Accruals	-35,529	-34,625
Total temporary differences	-40,206	-39,383
Deferred tax asset	8,845	8,664

The Company as the subsidiary of GE HealthCare Technologies Inc. is within the scope of the Organisation for Economic Co-operation and Development (OECD) Pillar Two model rules ("Pillar Two"). The Pillar Two legislation was substantively enacted in Norway, the jurisdiction in which the Company is incorporated. Upon enactment, the Pillar Two taxation regime (specifically the qualifying domestic minimum top-up tax ("QDMTT")) will come into effect from 1 January 2024, and the effective date of the income inclusion rule ("IIR") is 1 January 2024.

The Pillar Two legislation was not effective at the reporting date. The Norwegian Accounting Board has not made any changes in the Norwegian GAAP rules, or provided any other forms of guidance. As of the preparation date of the statutory financial statements, no exception to recognizing and disclosing information about deferred tax assets and liabilities related to Pillar Two income taxes is implemented. The current Norwegian GAAP rules does not provide sufficient guidance to assess the magnitude of a potential deferred tax liability related to the new rules, as the tax consequences from realization of underlying assets and liabilities are dependent on various future conditions. In most situations these are very difficult to estimate. Nor have there been any international guidelines or guidance to determine the amount of any deferred tax as a result of these rules.

According to Norwegian GAAP NRS 13 Uncertain liabilities and contingent assets, uncertain liabilities shall not be recognized if it is not possible to estimate the value reliably. It is the Company's view that it is not possible to estimate a reliable tax amount that can be included in the financial statements. Although assessing the full impact of Pillar Two is incomplete, the results of a preliminary analysis indicate that the Company and its subsidiaries will not qualify for applying the transitional Country-by-Country Reporting (CbCR) safe harbor in 2024. The impact from the potential top-up tax under Pillar Two is not expected to be material to the Company's financial statements.

NOTE 8 GROUP CONTRIBUTION

Current year the company submitted the following taxable group contribution

Provider	Receiver	Gross	Net
GE Healthcare Norge AS	GE Healthcare Norway Holding AS	15,590	12,160

Current year the company received the following non-taxable group contribution

Provider	Receiver	Gross
GE Healthcare Norway Holding AS	GE Healthcare Norge AS	15,590



GE Healthcare Norge AS

Financial Statements 2023

All figures in NOK '000

Notes

NOTE 9 INVENTORIES

	31.12.2023	31.12.2022
Stock of equipment	2,036	5,309
Equipment in transit	5,937	6,141
Stock of spare parts	639	858
Obsolescence	-4,647	-5,205
Total inventories	3,965	7,103

NOTE 10 CASH AND CASH EQUIVALENTS

The company has a bank account in Danske Bank that is included in GE group cash pool agreement. The balance is brought forward to GE Treasury and converted into short term receivable from group companies. Interest is calculated based on arm's length principle. The company also has a 5 000 000 NOK bank guarantee at DNB Bank as security for proper payment of employee withholding taxes. There are no restricted funds or collaterals at year end.

NOTE 11 EQUITY

	Share capital	Other paid-in equity	Retained earnings	Total equity
Equity 31.12.2022	1,114	95,469	0	96,583
Current year profit / loss			10,944	10,944
Paid taxable group contribution		-1,216	-10,944	-12,160
Received non-taxable group contribution		15,590		15,590
Equity 31.12.2023	1,114	109,842	0	110,956

The share capital consists of 1 114 000 shares of 1 000 NOK. All shares have equal rights. The company's shares are 100 % owned by GE Vingmed Ultrasound AS.

NOTE 12 ACCRUALS FOR FUTURE OBLIGATIONS

	31.12.2023	31.12.2022
Provision for standard and extended warranty	35,529	34,625
Total accruals for future obligations	35,529	34,625

Warranty provision is an accounting accrual based on best estimate.

NOTE 13 OTHER CURRENT LIABILITIES

	31.12.2023	31.12.2022
Sales commissions and bonuses	7,458	7,203
Vacation pay	6,584	6,326
Freight accrual	580	1,080
Sales related accruals	674	333
Other liabilities	755	117
Total other current liabilities	16,051	15,060

NOTE 14 PENSION COSTS AND LIABILITIES

The company has a defined contribution pension scheme that covers 43 people. It meets the requirements in the mandatory occupational pensions act. Contributions to the defined contribution scheme are recognized as expense in the profit and loss statement as incurred.

Additionally, the company has an agreed early retirement scheme (AFP). The AFP scheme is a tariff based lifelong retirement arrangement that can be withdrawn from the age of 62 organized by the main labour unions and the Norwegian state. It is a defined benefit multi-enterprise scheme, but is recognized in the accounts as a defined contribution scheme until reliable and sufficient information is available for the group to recognize its proportional share of pension cost, pension liability and pension funds in the scheme. The company's liabilities are therefore not recognized as debt in the balance sheet.

	2023	2022
AFP premium paid	687	692



Skattedirektoratet

Saksbehandler
Rune Tystad

Deres dato
29.09.2016

Vår dato
11.11.2016

Telefon
977 59 464

Deres referanse
Geir Atle Carlsen

Vår referanse
2016/996601

GENERAL ELECTRIC INTERNATIONAL INC filial av
utenlandsk foretak
Postboks 4766 Nydalen
0421 OSLO

Tillatelse til å utarbeide årsregnskap og årsberetning på engelsk språk for selskaper i General Electric-gruppen

Vi viser til deres brev av 29. september 2016 der dere søker om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk for følgende selskaper:

GE Healthcare AS,	org.nr. 914 829 674
GE Healthcare Holding AS,	org.nr. 987 015 225
Amersham Health Norge AS,	org.nr. 979 306 946
GE Healthcare Holding Norge AS,	org.nr. 988 963 755
GEFH AS,	org.nr. 990 400 156
GE Healthcare Clinical Systems Norway AS,	org.nr. 988 963 690
GE Healthcare Norge AS,	org.nr. 926 293 621
GE Vingmed Ultrasound AS,	org.nr. 938 937 583
GE Healthcare Europe GmbH - Branch Norway,	org.nr. 968 146 092
GE Capital AS,	org.nr. 987 058 765
GECAS Aircraft Leasing Norway AS,	org.nr. 985 551 685
GECAS EX-IM Leasing Norway AS,	org.nr. 894 570 652
GE Lighting AS,	org.nr. 910 904 396
Nuovo Pignone SPA NUF,	org.nr. 974 230 666
Vetco Gray Scandinavia AS,	org.nr. 990 441 545
Vetco Gray AS,	org.nr. 913 147 758
Presens AS,	org.nr. 976 876 385
Naxys AS,	org.nr. 993 277 983
Advantec AS,	org.nr. 887 471 282
NTOS Holding AS,	org.nr. 912 101 231
NTOS AS,	org.nr. 983 923 518
PII Ltd Norway Branch,	org.nr. 980 716 856
Thermodyn SAS Norway branch,	org.nr. 982 455 626
GE Energy (Norway) AS,	org.nr. 980 862 860
GE Wind Energy (Norway) AS,	org.nr. 881 520 532
Granite Services International Inc Norway branch,	org.nr. 985 604 908
GE Power Norway AS,	org.nr. 980 402 274

Postadresse
Postboks 9200 Grønland
0134 Oslo

Besøksadresse:
Se www.skatteetaten.no
Org.nr: 996250318
E-post: skatteetaten.no/sendepost

Sentralbord
800 80 000
Telefaks
22 17 08 60



GE Energy Connections AS,	org.nr. 937 025 440
GE Renewable Norway AS,	org.nr. 889 467 592
GE Energy Power Conversion France SAS Norway branch,	org.nr. 995 139 421
GE Energy Power Conversion Norway AS,	org.nr. 996 326 020
GE Energy Power Conversion UK Ltd Norway branch,	org.nr. 813 661 632
GE International Inc. NUF,	org.nr. 860 192 942

I tillegg søker dere om dispensasjon til å kunne utarbeide alle fremtidige selskapers årsregnskap og årsberetning på engelsk.

Skattedirektoratet gir på bakgrunn av en konkret helhetsvurdering de overnevnte selskaper dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen forutsetter at opplysningene som vedtaket baserer seg på ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Etter regnskapsloven § 3-4 tredje ledd kan det kun gis dispensasjon til navngitte regnskapspliktige, jf. definisjon av enkeltvedtak i forvaltningsloven § 2 første ledd bokstav b. Vi har derfor ikke hjemmel til å behandle søknaden knyttet til fremtidige selskaper. For å få dispensasjon for eventuelle fremtidige selskaper må dere søke konkret for de aktuelle selskapene.

Bakgrunn

Fra deres søknad gjengis:

General Electric Company er et børsnotert amerikansk konsern med virksomhet i mange land, herunder i Norge gjennom flere norske selskaper og filialer av utenlandske selskaper. Som et ledd i konsernets bestrebelser på å forenkle rapporteringer og informasjonsflyt, søkes det med dette om å få utarbeide årsregnskap og årsberetning på engelsk fra og med regnskapsåret 2016 for de selskaper og filialer som er spesifisert i vedlegg til denne søknaden.

De norske selskapene er lokalisert ulike steder i Norge, herunder Oslo, Sandvika, Horten, Stavanger og Bergensområdet og omfatter ulike typer bransjer. General Electric har ikke etablert en spesifikk konsernstruktur med en enkelt konsernspiss i Norge, men hvor det finnes flere delkonsern og enkeltstående selskaper avhengig av bransje.

Virksomheten er fullt ut rettet mot produksjon og salg av varer og tjenester til andre selskaper i Norge og utlandet. Det selges ikke noe direkte til forbrukere i Norge. Innenfor energi og olje/gass er General Electric aktive både på sokkelen og på land. Alle sentrale aktører og samarbeidspartnere er av internasjonal karakter, og innenfor bransjen beherskes og benyttes engelsk.



Innenfor helseområdet produseres det kontrastvæskemidler og ultralydmaskiner. Alt salg går til offentlige og private sykehus, leger og helseinstitusjoner. Det er i det alt vesentlige eksportrettet, med en liten andel salg og service i Norge, men ikke direkte mot forbrukermarkedet. Teknisk dokumentasjon, søknader om godkjenning i ulike land mv utarbeides på engelsk, og alle sentrale aktører innenfor bransjen benytter engelsk som arbeidsspråk.

Utover dette har man noen mindre virksomheter som blant annet forestår leasing av fly til utenlandske flyselskaper, salg av lysmateriell til grossister i Norge, samt utøver interne støttefunksjoner til norske og utenlandske konsernselskaper.

Selskapenes arbeidsspråk er engelsk, da man har tildels utstrakt samarbeid med andre konsernselskaper i utlandet. Dette forenkler og effektiviserer informasjonsflyt, analyser og rapporteringer, samt reduserer kostnader. Selskapene opererer i sektorer hvor engelsk er det klart dominerende språket. Morselskapets aksjonærer er utenlandske personer eller selskaper.

I flere av selskapene sitter det både norske og utenlandske styremedlemmer. Dette medfører at det i dag må utarbeides både norske og engelske versjoner av årsregnskaper og årsberetninger. Det er ressurskrevende, og kan også av og til gi opphav til tvil om oversettelse og uoverensstemmelser mellom engelsk og norsk versjon, og dermed unødvendige misforståelser.

Skattedirektoratets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap m.v., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i



proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter Skattedirektoratets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har Skattedirektoratet lagt særlig vekt på at selskapene og filialene inngår i et utenlandsk konsern og at selskapenes arbeidsspråk er engelsk. Videre er det vektlagt at selskapene opererer i sektorer hvor engelsk er det klart dominerende språket.

Vennligst oppgi vår referanse ved henvendelser i saken.

Med hilsen

Torstein Kinden Helleland
seniorrådgiver
Rettsavdelingen, foretaksskatt
Skattedirektoratet

Rune Tystad

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer